Idexx Laboratories (IDXX) Total Current Liabilities (2009 - 2026)

Idexx Laboratories (IDXX) has reported Total Current Liabilities for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 14.4% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 14.4% YoY), while the FY2025 annual figure was $1.1 billion, up 7.58% from the prior year.
• Total Current Liabilities came in at $1.3 billion for Q1 2026 at Idexx Laboratories, up from $1.1 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.3 billion in Q1 2026, with the low at $883.9 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Across the five-year window, Total Current Liabilities surged 87.73% in 2022 and fell 24.23% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $1.2 billion in 2022, then slipped by 23.0% to $951.5 million in 2023, then rose by 12.23% to $1.1 billion in 2024, then increased by 7.58% to $1.1 billion in 2025, then increased by 13.15% to $1.3 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.3 billion, $1.1 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.